Request for extraordinary general meeting

Oslo, 23 October 2013: DiaGenic ASA (DiaGenic) has received a request for the convening of an extraordinary general meeting from shareholders Corona Maritime AS and Tycoon Industrier AS, pursuant to section 5-7 (2)of the Norwegian Public Companies Act. It is requested that election of the board of directors is addressed.

The extraordinary general meeting will be held within the one month deadline set out in section 5-7 (2) of the Norwegian Public Companies Act. A formal notice will be distributed separately in due course, with a statutory notice period of three weeks.

Contact:

Hanne Skaarberg Holen, Chairman of the Board ( +47 9829 4591)

About DiaGenic ASA

DiaGenic is an innovative Norwegian diagnostic company that seeks to create value for patients, partners and investors by developing innovative and patient friendly in vitro diagnostic (IVD) products for early detection of diseases. The company’s proprietary concept implies that a disease evokes systemic responses in the blood unique for the disease, and which can be measured by using a blood sample. DiaGenic is a world leader in identifying gene expression signatures in blood and is focused on the development of IVD biomarker products in the field of Alzheimer’s disease. The company protects its technology through an extensive patent portfolio. DiaGenic is listed on the Oslo Stock Exchange. For more information please visit: www.diagenic.com